2016-11-11T13:32:33-06:00 2015-12-31 521392008 GELMAN ROSENBERG & FREEDMAN 4550 MONTGOMERY AVE SUITE 650N BETHESDA MD 208142930 990 2015-01-01 830431851 PATH VACCINE SOLUTIONS PATH 2062853500 2201 WESTLAKE AVENUE NO 200 SEATTLE WA 98121 OLIVIA D POLIUS CHIEF FINANCIAL OFFICER 2062853500 2016-11-11 1 3019519090 2015 2017-02-10 21:41:12Z OLIVIA D POLIUS 2201 WESTLAKE AVENUE NO 200 SEATTLE WA 98121 66233669 0 X WWW.PATH.ORG X 2006 WA SEE PART III, LINE 1. 7 2 0 0 0 0 24448784 45999268 0 0 315733 733017 7237 2587 24771754 46734872 36562862 28397080 0 0 0 0 0 0 0 10606165 9999989 47169027 38397069 -22397273 8337803 149044550 150830465 10278308 4059847 138766242 146770618 X THE MISSION OF PATH VACCINE SOLUTIONS (PVS) IS TO IMPROVE THE HEALTH OF CHILDREN IN LOW-INCOME COUNTRIES BY ACCELERATING THE DEVELOPMENT OF VACCINES THAT WILL BE EFFECTIVE AND AFFORDABLE FOR THOSE WHO NEED THEM MOST. FROM INITIAL DISCOVERY THROUGH CLINICAL TRIALS, PVS WORKS WITH COMMERCIAL PARTNERS, SUCH AS VACCINE MANUFACTURERS AND BIOTECHNOLOGY FIRMS, AND NONPROFIT PARTNERS, SUCH AS UNIVERSITIES AND RESEARCH INSTITUTIONS, TO SHORTEN THE TIMELINE FOR VACCINE DEVELOPMENT.PVS WORKS WITH PARTNERS TO DEVELOP NEW VACCINES BY PROVIDING FUNDING AND EXPERTISE IN PRECLINICAL DEVELOPMENT, MANUFACTURING, AND CLINICAL DEVELOPMENT, WITH A FOCUS ON LOW-RESOURCE COUNTRIES. IN RETURN, PARTNERS AGREE TO TERMS THAT HELP ENSURE THE RESULTING PRODUCTS ARE AFFORDABLE AND AVAILABLE IN DEVELOPING COUNTRIES. 0 0 38397069 28397080 PVS WORKS TO PREVENT DEATH AND DISEASE CAUSED BY DIARRHEA, PNEUMONIA, INFLUENZA, RESPIRATORY SYNCYTIAL VIRUS, AND POLIO AMONG CHILDREN AROUND THE WORLD. WE ACCELERATE THE DEVELOPMENT OF SAFE, EFFICACIOUS, AND AFFORDABLE VACCINES IN PARTNERSHIP WITH PUBLIC AND PRIVATE GROUPS. IN 2015, PVS CONTINUED OUR FIGHT AGAINST DIARRHEAL DISEASE, THE SECOND LEADING CAUSE OF DEATH AMONG CHILDREN IN THE DEVELOPING WORLD. TO COMBAT ROTAVIRUS, A MAJOR CAUSE OF SEVERE DIARRHEA, WE PARTNERED WITH SERUM INSTITUTE OF INDIA PVT. LTD. (SIIPL) TO STUDY A VACCINE THAT MAY REMAIN STABLE AND POTENT EVEN DURING EXTENDED PERIODS WITHOUT REFRIGERATION, ENABLING WIDER USE IN REMOTE COMMUNITIES. WE COMPLETED ENROLLMENT FOR A PHASE 3 EFFICACY STUDY OF THE VACCINE (THE LARGEST EVER UNDERTAKEN AMONG CHILDREN IN INDIA) AND BEGAN A STUDY TO EXAMINE CLINICAL LOT CONSISTENCY AND POTENTIAL INTERFERENCE WITH OTHER ROUTINE VACCINES. FINALLY, ROTAVAC , AN INDIAN-MADE VACCINE DEVELOPED WITH PATH SUPPORT, REMAINED ON TRACK FOR INTRODUCTION IN INDIA'S PUBLIC SECTOR IN 2016.OUR EFFORTS TO COMBAT ENTEROTOXIGENIC ESCHERICHIA COLI (ETEC) AND SHIGELLA, IMPORTANT CAUSES OF BACTERIAL DIARRHEAL ILLNESS, HAVE RESULTED IN THE INITIATION AND CONTINUATION OF NUMEROUS CLINICAL TRIALS. IN 2015, WE BEGAN A CLINICAL STUDY OF ETVAX, AN INACTIVATED, WHOLE CELL VACCINE CANDIDATE AGAINST ETEC, AT ICDDR,B IN BANGLADESH. WE ALSO WORKED WITH THE US NAVAL MEDICAL RESEARCH CENTER TO EVALUATE THE PROTECTIVE EFFICACY OF AN ETEC VACCINE CANDIDATE. THE EVALUATION IDENTIFIED POSITIVE TRENDS IN PROTECTION. TO PROTECT AGAINST SHIGELLA, WE PARTNERED WITH THE WALTER REED ARMY INSTITUTE OF RESEARCH TO STUDY A LIVE ATTENUATED VACCINE CANDIDATE IN CHILDREN FIVE TO NINE YEARS OF AGE. RESULTS REVEALED THE VACCINE TO BE SAFE AND IMMUNOGENIC. OUR WORK TO ADVANCE THE DEVELOPMENT OF LOW-COST, PEDIATRIC VACCINE CANDIDATES AGAINST THE PNEUMOCOCCUS BACTERIUM-THE TOP CAUSE OF SEVERE CHILDHOOD PNEUMONIA-PROGRESSED IN 2015 WITH THE CONTINUATION OF PHASE 1 AND 2 TRIALS IN AFRICA. IN THE GAMBIA, WE ARE EVALUATING A DECAVALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV-10) CANDIDATE, MANUFACTURED BY SIIPL. THE PCV-10 CANDIDATE IS DESIGNED TO BE AFFORDABLE AND FOCUSES ON THE TEN SEROTYPES CAUSING THE MOST CASES OF INVASIVE PNEUMOCOCCAL DISEASE IN AFRICA AND ASIA, WHERE MOST PNEUMOCOCCAL DEATHS OCCUR. IN KENYA, WE ARE STUDYING A PNEUMOCOCCAL WHOLE CELL VACCINE CANDIDATE DEVELOPED IN PARTNERSHIP WITH BOSTON CHILDREN'S HOSPITAL THAT HAS THE POTENTIAL TO PROVIDE BROAD PROTECTION ACROSS THE MANY SEROTYPES OF PNEUMOCOCCUS AT A LOW PRICE. BOTH VACCINE CANDIDATES ARE DESIGNED TO MEET COST AND DISEASE COVERAGE NEEDS IN LOW-RESOURCE SETTINGS AND COULD HELP FREE UP DONOR FUNDS FOR OTHER GLOBAL HEALTH PRIORITIES IF SUCCESSFUL. 38397069 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0 1 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 X 7 2 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 0 0 0 WA X X OLIVIA POLIUS CHIEF FINANCIAL OFFICER 2062853500 2201 WESTLAKE AVE SUITE 200 SEATTLE WA 98121 STEPHEN B DAVIS CHAIR AND PRESIDENT 1.00 39.00 X X 0 607729 59038 PENNY HEATON VICE CHAIR 1.00 0.00 X X 0 0 0 OLIVIA D POLIUS TREASURER 1.00 39.00 X X 0 264997 46727 AMIE E BATSON DIRECTOR 1.00 39.00 X 0 283722 30937 DANIEL LASTER DIRECTOR / GENERAL COUNSEL 1.00 39.00 X 0 268812 39328 DAVID C KASLOW DIRECTOR 1.00 39.00 X 0 316540 58018 CHRIS KARP DIRECTOR 1.00 0.00 X 0 0 0 DAVID A ALLI SECRETARY 20.00 20.00 X 0 160737 30665 0 1902537 264713 0 0 1 0 NORTHERN TRUST 50 S LASALLE ST CHICAGO IL 60675 ASSET MANAGEMENT 121287 1 84282 45914986 45999268 713980 713980 19517834 19498797 19037 19037 19037 OTHER REIMBURSEMENTS 900099 2565 2565 MISCELLANEOUS 900099 22 22 2587 46734872 0 0 735604 23229760 23229760 5167320 5167320 4678 4678 121287 121287 554844 554844 6285 6285 278113 278113 11495 11495 5000 5000 1501413 1501413 129863 129863 146473 146473 SUBCONTRACTORS 6968234 6968234 EQUIPMENT R&M 108073 108073 LAB SUPPLIES 104819 104819 STORAGE 57545 57545 1867 1867 38397069 38397069 0 0 15650996 17554485 60119568 59593963 126845 168331 227541 127204 163708 100337 72983433 73413349 149044550 150830465 10278308 4059847 10278308 4059847 X 37582 18107 138728660 146752511 138766242 146770618 149044550 150830465 X 8337803 -247862 -85565 X 0 1 X 1 0 X X 1 PATH 911157127 7 1 38397069 0 1 38397069 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 227541 127204 100337 100337 1 CENTRAL AMERICA AND THE CARIBBEAN 0 0 PROGRAM SERVICES PRODUCT DEVELOPMENT 165 EAST ASIA AND THE PACIFIC 0 0 PROGRAM SERVICES PRODUCT DEVELOPMENT 181906 EAST ASIA AND THE PACIFIC 0 0 GRANTMAKING 561337 EUROPE 0 0 PROGRAM SERVICES PRODUCT DEVELOPMENT 519205 EUROPE 0 0 GRANTMAKING 1255350 NORTH AMERICA 0 0 PROGRAM SERVICES PRODUCT DEVELOPMENT 4839 SOUTH AMERICA 0 0 PROGRAM SERVICES PRODUCT DEVELOPMENT 7281 SOUTH ASIA 0 10 PROGRAM SERVICES PRODUCT DEVELOPMENT 761932 SOUTH ASIA 0 0 GRANTMAKING 3125936 SUB-SAHARAN AFRICA 0 1 PROGRAM SERVICES PRODUCT DEVELOPMENT 1173248 SUB-SAHARAN AFRICA 0 0 GRANTMAKING 224697 0 10 0 1 0 11 3292015 4523881 7815896 SUB-SAHARAN AFRICA PRODUCT DEVELOPMENT 15000 CHECK/WIRE SOUTH ASIA PRODUCT DEVELOPMENT 20000 CHECK/WIRE EUROPE PRODUCT DEVELOPMENT 60000 CHECK/WIRE EUROPE PRODUCT DEVELOPMENT 74235 CHECK/WIRE EUROPE PRODUCT DEVELOPMENT 74902 CHECK/WIRE SOUTH ASIA PRODUCT DEVELOPMENT 120452 CHECK/WIRE SOUTH ASIA PRODUCT DEVELOPMENT 145781 CHECK/WIRE EUROPE PRODUCT DEVELOPMENT 150000 CHECK/WIRE SUB-SAHARAN AFRICA PRODUCT DEVELOPMENT 209697 CHECK/WIRE EUROPE PRODUCT DEVELOPMENT 275000 CHECK/WIRE SOUTH ASIA PRODUCT DEVELOPMENT 296686 CHECK/WIRE SOUTH ASIA PRODUCT DEVELOPMENT 350764 CHECK/WIRE SOUTH ASIA PRODUCT DEVELOPMENT 440000 CHECK/WIRE SOUTH ASIA PRODUCT DEVELOPMENT 457534 CHECK/WIRE EAST ASIA AND THE PACIFIC PRODUCT DEVELOPMENT 559018 CHECK/WIRE SOUTH ASIA PRODUCT DEVELOPMENT 637969 CHECK/WIRE SOUTH ASIA PRODUCT DEVELOPMENT 652080 CHECK/WIRE EUROPE PRODUCT DEVELOPMENT 770571 CHECK/WIRE EUROPE PRODUCT DEVELOPMENT -153189 CHECK/WIRE 14 4 1 0 0 0 0 0 PART I, LINE 2: SUBRECIPIENTS MUST SUBMIT PROGRESS REPORTS THAT ARE REVIEWED BY RESPONSIBLE PATH PROGRAM MANAGERS AND PROGRAM ADMINISTRATORS TO ENSURE THAT PROGRAM GOALS ARE ATTAINED IN ACCORDANCE WITH AGREEMENT REQUIREMENTS. THE RESPONSIBLE PROGRAM MANAGERS AND PROGRAM ADMINISTRATORS CONTACT SUBRECIPIENTS WITH QUESTIONS OR FOLLOW UP ON ANY AREA OF CONCERN. IN SOME CASES, SUBAWARD TERMS MAY REQUIRE SPECIFIED DELIVERABLES IN ADDITION TO, OR IN LIEU OF, TECHNICAL AND FINANCIAL REPORTS. IN ADDITION, DISCRETIONARY ON-SITE VISITS ARE CONDUCTED TO EVALUATE BOTH COMPLIANCE WITH THE PROGRAMMATIC OBJECTIVES OF THE PROJECT AND THE APPROPRIATENESS OF THE SUBRECIPIENT'S ADMINISTRATIVE SYSTEMS AND PROCESSES. 1 EMMES CORPORATION 401 NORTH WASHINGTON ST 700 ROCKVILLE MD 20850 541058268 N/A 21013 PRODUCT DEVELOPMENT WASHINGTON UNIVERSITY IN ST LOUIS ONE BROOKINGS DR CAMPUS BOX 1054 ST LOUIS MO 63130 430653611 501(C)(3) 33717 PRODUCT DEVELOPMENT LANKENAU INSTITUTE FOR MEDICAL RESEARCH 100 LANCASTER AVE WYNNEWOOD PA 19096 232175659 501(C)(3) 58334 PRODUCT DEVELOPMENT TULANE EDUCATIONAL FUND 1430 TULANE AVENUE TB-32 NEW ORLEANS LA 701122632 720423889 501(C)(3) 83465 PRODUCT DEVELOPMENT HARVARD UNIVERSITY SCHOOL OF PUBLIC HEALTH INTERNATIONAL HEALTH 677 HUNTINGTON AVENUE BOSTON MA 02115 042103580 501(C)(3) 127753 PRODUCT DEVELOPMENT UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE CENTER FOR VACCINE DEV 685 WEST BALTIMORE ST ROOM 480 BALTIMORE MD 21201 526002033 501(C)(3) 141038 PRODUCT DEVELOPMENT UNIVERSITY OF MARYLAND SCH OF MED INST FOR GENOME SCIENCES 801 W BALTIMORE ST BIOPARK II 6 FL BALTIMORE MD 21201 526002033 501(C)(3) 150934 PRODUCT DEVELOPMENT UNIVERSITY OF FLORIDA 219 GRINTER HALL PO BOX 115500 GAINESVILLE FL 326115500 596002052 501(C)(3) 152772 PRODUCT DEVELOPMENT KANSAS STATE UNIVERSITY 2 FAIRCHILD HALL DEPT OF GRAIN SCIENCE AND INDUSTRY MANHATTAN KS 66506 480771751 501(C)(3) 160000 PRODUCT DEVELOPMENT JHU BLOOMBERG SCHOOL OF PUBLIC HEALTH 615 N WOLFE STREET BALTIMORE MD 21205 131687001 501(C)(3) 174680 PRODUCT DEVELOPMENT UNITED STATES NAVAL MEDICAL RESEARCH CENTER 503 ROBERT GRANT AVE SILVER SPRING MD 209107500 470100048 GOV 212567 PRODUCT DEVELOPMENT UNIVERSITY OF ALABAMA AT BIRMINGHAM 701 20TH STREET SOUTH AB 1170 BIRMINGHAM AL 35294 636005396 501(C)(3) 250000 PRODUCT DEVELOPMENT FINA BIOSOLUTIONS LLC 9430 KEY WEST AVE SUITE 200 ROCKVILLE MD 20850 205448275 N/A 351245 PRODUCT DEVELOPMENT UNIVERSITY OF MARYLAND BALTIMORE PO BOX 41428 BALTIMORE MD 212036428 526002033 501(C)(3) 400000 PRODUCT DEVELOPMENT NOVAVAX INC 20 FIRSTFIELD ROAD ROCKVILLE MD 20878 222716046 N/A 483726 PRODUCT DEVELOPMENT FAMILY HEALTH INTERNATIONAL 360 359 BLACKWELL ST SUITE 200 DURHAM NC 27701 237413005 501(C)(3) 514512 PRODUCT DEVELOPMENT JOHNS HOPKINS UNIVERSITY OFFICE OF RESEARCH ADMIN 615 N WOLFE ST W1100 BALTIMORE MD 21205 131687001 501(C)(3) 570533 PRODUCT DEVELOPMENT BOSTON CHILDREN'S HOSPITAL 300 LONGWOOD AVENUE BOSTON MA 02115 042774441 501(C)(3) 913516 PRODUCT DEVELOPMENT WALTER REED ARMY INSTITUTE OF RESEARCH 503 ROBERT GRANT DRIVE SILVER SPRING MD 209107500 520664528 GOV 1031865 PRODUCT DEVELOPMENT AFFINIVAX INC 190 GRANT STREET LEXINGTON MA 02420 464701432 N/A 3269285 PRODUCT DEVELOPMENT PATH 2201 WESTLAKE AVE SUITE 200 SEATTLE WA 98121 911157127 501(C)(3) 14137772 PRODUCT DEVELOPMENT ADVANCED BIOSCIENCE LABORATORIES INC 9800 MEDICAL CENTER DRIVE BUILDING D ROCKVILLE MD 20850 621242262 N/A -8680 PRODUCT DEVELOPMENT WASHINGTON UNIVERSITY IN ST LOUIS ONE BROOKINGS DRIVE CAMPUS BOX 1054 1054 ST LOUIS MO 63130 430653611 501(C)(3) -271 PRODUCT DEVELOPMENT OKLAHOMA STATE UNIVERSITY 203 WHITEHURST HALL STILLWATER OK 74078 736017987 501(C)(3) -17 PRODUCT DEVELOPMENT 17 4 PART I, LINE 2: SUBRECIPIENTS MUST SUBMIT PROGRESS REPORTS THAT ARE REVIEWED BY RESPONSIBLE PATH PROGRAM MANAGERS AND PROGRAM ADMINISTRATORS TO ENSURE THAT PROGRAM GOALS ARE ATTAINED IN ACCORDANCE WITH AGREEMENT REQUIREMENTS. THE RESPONSIBLE PROGRAM MANAGERS AND PROGRAM ADMINISTRATORS CONTACT SUBRECIPIENTS WITH QUESTIONS OR FOLLOW UP ON ANY AREA OF CONCERN. IN SOME CASES, SUBAWARD TERMS MAY REQUIRE SPECIFIED DELIVERABLES IN ADDITION TO, OR IN LIEU OF, TECHNICAL AND FINANCIAL REPORTS. IN ADDITION, DISCRETIONARY ON-SITE VISITS ARE CONDUCTED TO EVALUATE BOTH COMPLIANCE WITH THE PROGRAMMATIC OBJECTIVES OF THE PROJECT AND THE APPROPRIATENESS OF THE SUBRECIPIENT'S ADMINISTRATIVE SYSTEMS AND PROCESSES. 0 0 0 0 0 0 0 0 0 STEPHEN B DAVIS CHAIR AND PRESIDENT 0 458417 0 147592 0 1720 0 31000 0 28038 0 666767 0 0 OLIVIA D POLIUS TREASURER 0 263202 0 0 0 1795 0 31000 0 15727 0 311724 0 0 AMIE E BATSON DIRECTOR 0 283722 0 0 0 0 0 30029 0 908 0 314659 0 0 DANIEL LASTER DIRECTOR / GENERAL COUNSEL 0 267092 0 0 0 1720 0 31000 0 8328 0 308140 0 0 DAVID C KASLOW DIRECTOR 0 314890 0 0 0 1650 0 31000 0 27018 0 374558 0 0 DAVID A ALLI SECRETARY 0 160737 0 0 0 0 0 17721 0 12944 0 191402 0 0 PART I, LINE 3 PVS RELIES ON A RELATED ORGANIZATION, PATH, TO DETERMINE COMPENSATION. PATH USES THE FOLLOWING TO ESTABLISH COMPENSATION OF THE EXECUTIVE DIRECTOR: - COMPENSATION COMMITTEE - INDEPENDENT COMPENSATION CONSULTANT - COMPENSATION SURVEY OR STUDY - APPROVAL BY THE BOARD OR COMPENSATION COMMITTEE FORM 990, PART VI, SECTION B, LINE 11 THE FORM 990 WAS PREPARED BY AN OUTSIDE ACCOUNTING FIRM (GELMAN, ROSENBERG & FREEDMAN) USING INFORMATION PROVIDED BY PATH ACCOUNTING SERVICES STAFF. PATH SENIOR MANAGEMENT REVIEWED THE DRAFT FORM. A COPY OF THE DRAFT WAS SENT TO PATH'S BOARD OF DIRECTORS FOR COMMENT. AFTER THE COMMENT PERIOD, THE CHIEF FINANCIAL OFFICER SIGNED AND FILED THE RETURN. FORM 990, PART VI, SECTION B, LINE 12C PVS HAS POLICIES AND PROCEDURES TO ADDRESS CONFLICTS OF INTEREST. PATH MANAGEMENT AND ALL STAFF ABOVE A DESIGNATED LEVEL IN THE ORGANIZATION MUST COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM EACH YEAR. ALL FORMS ARE REVIEWED AND KEPT ON FILE. A CONFLICT MANAGEMENT PLAN IS DEVELOPED FOR ANY EMPLOYEE WITH A SIGNIFICANT ACTUAL OR PERCEIVED CONFLICT OF INTEREST. PATH ALSO HAS A WELL-DEFINED PROCEDURE FOR IDENTIFYING AND REPORTING ACTUAL AND POTENTIAL CONFLICTS OF INTEREST AMONG BOARD MEMBERS. NEW BOARD MEMBERS ARE ASKED TO COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM WITHIN 30 DAYS OF JOINING THE BOARD AND TO COMPLETE A NEW FORM ANNUALLY THEREAFTER. IN ADDITION, MEMBERS ARE REMINDED TO REPORT ANY NEW ISSUES THAT ARISE OUTSIDE OF THE ANNUAL DISCLOSURE PERIOD. THE DISCLOSURE FORMS ARE REVIEWED BY PATH'S GENERAL COUNSEL, AND, IF ANY ACTUAL OR POTENTIAL CONFLICTS ARE IDENTIFIED, GENERAL COUNSEL MAKES A RECOMMENDATION TO THE CHAIR OF THE GOVERNANCE COMMITTEE AND THE CHAIR OF THE BOARD FOR A MANAGEMENT PLAN TO PROPERLY MANAGE ANY CONFLICTS. A FORMAL MANAGEMENT PLAN IS THEN AGREED UPON WITH THE BOARD MEMBER, AND THE ENTIRE BOARD OF DIRECTORS IS INFORMED AT THE NEXT REGULARLY SCHEDULED BOARD MEETING. FORM 990, PART VI, SECTION C, LINE 19 PVS'S GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE TO THE PUBLIC UPON REQUEST; MOST DOCUMENTS ARE ALSO AVAILABLE ONLINE. FORM 990, PART XI, LINE 9: FROM TIME TO TIME, UNSPENT AWARD FUNDS (OR UNUSED OBLIGATIONS) MAY BE RETURNED TO A FUNDER FOR A VARIETY OF REASONS INCLUDING, BUT NOT LIMITED TO, EARLY TERMINATION OF A PROJECT BY A FUNDER, OR A REDUCTION IN FUNDS REQUIRED TO ACCOMPLISH A PROJECT'S SCOPE OF WORK. -85,565. PATH 2201 WESTLAKE AVE SUITE 200 SEATTLE WA 98121 911157127 GLOBAL HEALTH WA 501(C)(3) LINE 7 N/A 0 PATH DRUG SOLUTIONS 280 UTAH AVENUE SUITE 250 SAN FRANCISCO CA 94080 943384500 DEVELOPMENT & DISTRIBUTION OF SAFE, EFFECTIVE, AND AFFORDABLE MEDICINES CA 501(C)(3) LINE 11A PATH 1 FOUNDATION FOR APPROPRIATE TECHNOLOGIES IN HEALTH - SWITZERLAND 207 ROUTE DE FERNEY 1218 LE GRAND-S GENEVA SZ EDUCATIONAL AND SCIENTIFIC PROMOTION OF HEALTH SZ 501(C)(3) PATH 1 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0